


**10-year follow-up of the prospective H96 trial by the LYSA / SFGM-TC study group:
risk-adapted single or tandem autologous stem-cell transplantation strategy remains appropriate
for first relapsed or refractory Hodgkin lymphoma with long-term follow-up**

245 Hodgkin lymphoma patients
H96 trial by the LYSA / SFGM-TC study group

Intermediate-risk group (n=95)

one risk factor at first relapse*



single autologous stem-cell transplantation

Poor-risk group (n=150)

primary refractory Hodgkin lymphoma (n=77)
or ≥ 2 risk factors at first relapse* (n=73)



tandem autologous stem-cell transplantation

*relapse < 12 months, stage III or IV at relapse and/or relapse in a previously irradiated site

10-year follow-up

64%

Freedom from second failure
(intent-to-treat analysis)

41%

70%

Overall Survival
(intent-to-treat analysis)

47%